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Abstract: Chaperone therapy is a newly developed molecular approach to lysosomal diseases, a group of human genetic 
diseases causing severe brain damage. We found two valienamine derivatives, N-octyl-4-epi-β-valienamine (NOEV) and 
N-octyl-β-valienamine (NOV), as promising therapeutic agents for human β-galactosidase deﬁ  ciency disorders (mainly 
GM1-gangliosidosis) and β-glucosidase deﬁ  ciency disorders (Gaucher disease), respectively. We brieﬂ  y reviewed the his-
torical background of research in carbasugar glycosidase inhibitors. Originally NOEV and NOV had been discovered as 
competitive inhibitors, and then their paradoxical bioactivities as chaperones were conﬁ  rmed in cultured ﬁ  broblasts from 
patients with these disorders. Subsequently GM1-gangliosidosis model mice were developed and useful for experimental 
studies. Orally administered NOEV entered the brain through the blood-brain barrier, enhanced β-galactosidase activity, 
reduced substrate storage, and improved neurological deterioration clinically. Furthermore, we executed computational 
analysis for prediction of molecular interactions between β-galactosidase and NOEV. Some preliminary results of compu-
tational analysis of molecular interaction mechanism are presented in this article. NOV also showed the chaperone effect 
toward several β-glucosidase gene mutations in Gaucher disease. We hope chaperone therapy will become available for 
some patients with GM1-gangliosidosis, Gaucher disease, and potentially other lysosomal storage diseases with central 
nervous system involvement.
Keywords: Chaperone, Valienamine, Lysosomal disease, Lysosomal enzyme, β-Galactosidase, β-Glucosidase, 
GM1-gangliosidosis, Gaucher disease
Introduction
Lysosome is one of the cellular organelles where various high molecular endogenous or exogenous 
compounds are systematically digested under the acidic condition.
1 This physiological catalytic process 
is disturbed if mutations occur in one of the genes coding for the hydrolytic enzymes in the lysosome. 
Celllular dysfunctioin caused by an excessive storage of substrates ensues, and a genetic metabolic 
disease (lysosomal disease) develops clinically in humans and other animals with neurological and 
other somatic manifestations. This concept was ﬁ  rst proposed for glycogen storage disease type I.
2
Since the mid-1960s, attempts have been made to the development of therapy for patients with 
lysosomal diseases. Theorectically enzyme replacement therapy was the most promising approach, and 
eventually shown to be effective for Gaucher disease patients, the most prevalent metabolic storage 
disorder of humans.
3 This approach has been extended to other lysosomal diseases. However, the effect 
has not been conﬁ  rmed to brain pathology in patients with neurological manifestations.
GM1-gagliosidosis is one of the lysosomal diseases with storage of ganglioside GM1, keratan sulfate, and 
glycoprotein-derived oligosaccharides, presenting clinically with progressive neurological deterioration 
mainly in infancy and childhood.
4 This disease has been our major target of research for more than 40 years. 
We analyzed correlation of phenotypic manifestations with storage compounds,
5 enzyme activities,
6,7 and 
enzyme molecules.
8,9 Finally we moved to molecular pathology of β-galactosidase.
10
In parallel with with these experiments, in the early 1990s, we started molecular analyses of two 
genetically distinct human disease groups, β-galactosidosis (β-galactosidase deﬁ  ciency disorders) caused 
by β-galactosidase gene mutations
4 and Fabry disease caused by α-galactosidase A gene mutations.
11 
A paradoxical phenomenon was found that galactose itself and anologous low molecular weight 8
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competitive inhibitors could serve as chemical 
chaperones to induce expression of catalytic 
activities of mutant enzymes after stabilization and 
successful intracellular transport to the lysosome 
in the cells. We reported this enhancement ﬁ  rst in 
Fabry disease,
12,13 and then in GM1-gangliosidosis
14 
and Gaucher disease.
15
After our early studies on galactose and 
1-deoxygalactonojirimycin (DGJ), we developed 
new valienamine derivatives, N-octyl-4-epi-β-
valienamine (NOEV) and N-octyl-β-valienamine 
(NOV) as chemical chaperones for mutant 
β-galactosidase and β-glucosidase proteins, respec-
tively, to restore the enzyme activity in somatic 
cells from patients with GM1-gangliosidosis and 
Gaucher disease.
14–16 We hope that this phenom-
enon will be applied to development of novel 
molecular therapeutic approach to lysosomal dis-
eases, particularly with severe brain damage, in 
the near future. In this article we summarize 
our experimental results of chaperone effect 
and chaperone therapy mainly on NOEV for 
GM1-gangliosidosis.
Competitive Inhibitors 
of Lysosomal Enzymes
Carbasugar glycosidase inhibitors 
and related bioactive compounds
Carbasugars, previously known as pseudosugars, 
are a family of sugar mimics currently attracting 
interest among researchers in glycobiology and 
chemistry ﬁ  elds.
17–19 The ﬁ  rst example of carba-
α-talopyranose was synthesized and called 
“pseudosugars.”
20 Later, naturally occurring 
bioactive carbasugar, 5a-carba-α-D-galactopyra-
nose, was discovered.
21 Carbasugars are (hydroxy-
methyl)-branched-chain cyclitols. They are 
topologically similar to normal sugars particularly 
in the arrangement of the hydroxyl and hydroxy-
methyl groups, but have the oxygen atom of the 
pyranose or furanose ring replaced by methylene. 
Humans cannot differentiate carbaglucose from 
true glucose by their taste.
22 Furthermore carba-
hexopyranoses exist in structurally stable α- and 
β-anomer forms which are not interconvertible. 
Therefore, chemical modiﬁ  cation at C-1 positions 
may be possible, providing biologically interesting 
compounds. Potent glycosidase inhibitors NOEV 
1 and NOV 2 (Fig. 1A) are synthetic 5,5a-unsaturated 
5a-carba-β-galacto and glucopyranosylamine 
derivatives, respectively.
In 1970, agrochemical antibiotic validamycin 
A 3 and homologues were discovered
23 and have 
so far been utilized to control sheath bright disease 
of rice plant (Fig. 1B). During their structural 
elucidation, three components were isolated: 
valienamine 5, validamine 6,
24 and valiolamine 7.
25 
These compounds are strong α-glucosidase inhib-
itors themselves. In 1976, α-amylase inhibitor 
acarbose 4 composed of 5 was discovered
26 and 
has been clinically used to control diabetes.
Structural modiﬁ  cation 
of valienamine
The enzyme inhibitory potency of 4 has been attrib-
uted to the core structure of methyl acarviosin 10, 
a strong α-glucosidase inhibitor, and considered to 
be an analogue of transition-state structure postu-
lated for enzymatic hydrolysis of maltose
27 
(Fig. 1C). The potency of 3 has been attributed to 
strong trehalase inhibition in vitro by validoxyl-
amine A 9 that mimicks the transition-state structure 
for hydrolysis of trehalose with trehalase. The 
valienamine moiety of 9 and 10 holds the pyranoid 
oxonium ion structures and binds more ﬁ  rmly to 
the corresponding active sites of enzymes via 
an imminium ion. Thus, they are competitive 
inhibitors, explaining a structural correlation 
between inhibitors and substrates. This knowledge 
opened up the possibility for development of 
therapeutically useful carbasugar derivatives. Thus, 
chemical modiﬁ  cation of three components 5–7 
was stimulated by successful medical application 
of 4 (Fig. 1B), leading to a ﬁ  nding of semisynthetic 
voglibose 8, N-(1,3-dihydroxyprop-2-yl)valiolamine 
that is fully compatible to 4.
28,29
One of the authors (SO) became interested in 
chemical modiﬁ  cation of 5 and 6, and designed some 
stereoisomers by analogy of the structural relation-
ship between enzyme inhibitors and substrates. 
However, both the C-1 epimers of 5 and 6 unexpect-
edly lacked activity against β-glucosidase. Then 
valienamine-type glycosidase inhibitors 11–13 with 
β-gluco, α-manno, and β-galacto conﬁ  gurations, 
expected to be speciﬁ  c inhibitors of the corresponding 
hydrolases, were synthesized
30,31 (Fig. 1D). How-
ever, notable inhibitory activity could not be observed 
for any of them. Bioassay of the activity was carried 
out routinely using commercially available glycosi-
dases. Although simple chemical modiﬁ  cation of 
these amines, such as N-alkylation, might have 
improved their potency, the activity of intact amines 9
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should be a reliable hallmark for further development 
of its related compounds. Undoubtedly, biochemical 
features of 5 and 6 have been important models for 
further successful development.
Glycocerebrosidase inhibitors: 
carbaglycosylceramides
Some glycosylamides are signiﬁ  cant immuno-
modulators.
32 We prepared some carbasugar 
analogues, such as compound 14, as bioactive 
glycosylamides
33 (Fig. 1E). This result suggested 
that the carbohydrate moiety of glycolipids could 
possibly be replaced to give rise to biologically 
active carbohydrate mimics.
Then a carbasugar mimic 15 of glucosylce-
ramide was found to be a moderate inhibitor of 
glucocerebrosidase.
34 Further attempts were made 
to prepare valienamine analogues 16 and 17, 
carbaglucosyl and carbagalactosylceramides,
35 
which exhibited potent and speciﬁ  c inhibitory 
activity against the corresponding gluco- (IC50, 
0.3 μM; bovine liver) and galacto-cerebrosidases 
(IC50, 2.7 μM; bovine liver).
N-Alkyl valienamines, potent 
β-galactosidase inhibitors
Complex ceramide chains were synthetically 
inaccessible. We therefore began to modify the struc-
ture by introducing a simple substitution of ceramide 
chain. Replacement with a simple aliphatic chain 
resulted in an increase of inhibitory activity
36 
(Fig. 1D). Table 1 shows enzyme inhibitory activity 
of N-alkyl derivatives 1, 2, 11a–d, and 13a–c 
[R=(CH2)nCH3]toward some glycosidases.
19,37 
N-Octyl derivatives 1 and 2 were most promising for 
medical application.
38 Biochemical role of N-octyl 
portion was predicted also by computer-assisted 
simulation studies (Sakakibara, unpublished data).
Preparative studies on valienamine 
type inhibitors
For further development of carbasugar chemistry, 
simple synthetic precursors are required. Diels-
Alder endo-adduct 18(+), (–) of furan and acrylic 
acid has been useful for this purpose. Preparative 
intermediates reported in previous studies
19 could 
also be provided as optically pure forms from 
common hexopyranoses
39 providing a convenient 
link of carba to true sugars. Optical resolution of 
racemic 18 could be readily conducted through 
fractional crystallization of the diastereomeric salt 
with optically active α-phenylethylamines,
40 or 
enantioselective hydrolysis of the racemic 
2-chloroethyl epoxy esters by means of pig liver 
esterase (Sugai et al. unpublished data).
Typical routes to valienamines related to NOEV 1 
and NOV 2 were briefly described
41 (Fig. 2A). 
Optically resolved endo-adduct 18(–) with 
L-stereochemistry was converted into 1,6-dibromo-1,6-
dideoxy-β-carbaglucose 20 through the triol 19. 
Elimination of  20 with 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) gave the conjugate alkadiene 21, which 
was transformed into 1,4-dibromides 22α,β. The 
primary bromo group was ﬁ  rst replaced with an 
acetate ion and then the secondary one with azide 
anion to give α,β-mixture of the azide precursors 
23α,β. The azido function was reduced with H2S or 
Ph3P to give the free bases 5 and 11.
Effective N-alkylation of 11 is important for 
provision of active compounds. Compound 23β 
was protected and reduced (→24). The free amine 
24 was treated with a series of acid chlorides to 
give the amides (25). Reduction of 25 with lithium 
aluminum hydride (LAH) (→26), followed by 
deprotection, afforded the N-alkyl valienamines 
(→NOV 2, 11a–d) in good yields.
36
NOEV 1 is the 4-epimer of 2. Preparation of 
1 was ﬁ  rst conducted cumbersomely by Walden 
inversion at C-4 of 2 through oxidation of 4-OH, 
followed by selective reduction.
38 Alternatively, 
18(+) was converted into the bromo acetate (27), 
which was cleaved with HBr to give the tribromide 
(28) (Fig. 2B). Compound 28 was treated with 
methoxide and the resulting anhydride was opened 
and then acetylated to give the dibromide (29). 
Dehydrobromination (→30) followed by protec-
tion gave the alkadiene 31. Treatment with bromine 
gave the 1,4-dibromide (32), which was similarly 
converted into the bromide 33. Thus 33 was simi-
larly transformed into the β-valienamine 13 with 
β-galacto configuration. Modification of the 
β-galactose-type valienamine will be achieved by 
direct displacement of bromide 33 with alkyl amine 
(→34). The substitution reaction selectively occurs 
as expected by neighboring assistance of the 
2-acetoxyl or through direct SN2 fashion to afford, 
after deprotection, N-alkyl-4-epi-β-valienamines 
(13a–c) including NOEV.
37
Transition-state type glycosidase inhibitor valien-
amines have thus been recognized as desirable 
carbohydrate mimics for designing new glycosidase 
inhibitors. Current technical difﬁ  culty is comparative 10
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Figure 1. Structures of valienamines and related compounds. 
1A) N-Octyl-4-epi-β-valienamine (NOEV) and N-octyl-β-valienamine 
(NOV). 1B) Antibiotic validamycin A and α-amylase inhibitor acarbose. 
Carbaglycosylamine-type α-glucosidase inhibitors: valienamine, 
validamine, and valiolamine. 1C) Validoxylamine A and methyl 
acarviosin are mimicking the postulated transition-state structures 
for hydrolysis of trehalose and maltose, respectively. 1D) Some 
biologically interesting valienamine analogues and N-alkyl derivatives 
[R = (CH2)nCH3]. 1E) Biologically active carbaglucosylamide and 
carbaglucosylceramide, and chemically modified unsaturated 
derivatives.  
inaccessibility to the carbahexose skeletons. Recently, 
we identiﬁ  ed some routes to carbasugars through 
chemical transformation of (–)-vibo-quercitol derived 
from myo-inositol by biogenesis (Fig. 2C).
42,43 This 
route establishes a link between naturally abundant 
cyclitols and chiral carbasugars.
Future aspect
Carbaglycosylamines are chemically stable 
(hydroxymethyl) aminocylitols and expected 
to play roles as non-hydrolyzable mimics of 
glycopyranosylamines.
43,44 Diverse modiﬁ  cation 
of the biochemical and topologic nature of 11
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Table 1. A) Inhibitory activity [Ki (μM)] of some N-alkyl-4-epi-β-valienamines against three glycosidases.
Compound n β-Galactosidase
a α-Galactosidase
b β-Glucosidase
c
β-Galacto type  1 7 0.87 3.1 3.1
13a 5 2.3 2.7 1.2
13b 9 0.13 1.9 2.5
13c 11 0.01 4.4 0.87
aBovine liver, 
bGreen coffee beans, 
cAlmonds.
Table 1. B) Inhibitory activity [Ki (μM)] of some N-alkyl-β-valienamines against glucocerebrosidase.
Compound n Glucocerebrosidase
d
β-Gluco type  2 7 0.03
11a 5 0.3
11b 9 0.07
11c 11 0.12
11d 13 0.3
dMouse liver.
carbaglycosylamines may be achieved by substitu-
tion at the anomeric position, unsaturation at C-5 
and C-5a, and hydroxylation at C-5 and/or C-5a, 
leading to improvement of biological function. As 
shown by the inhibitory activity of the N-alkyl 
derivatives 11a–d and 13a–c of β-valienamines, the 
inclusion of hydrophobic N-alkyl chains is likely to 
contribute to improvement of its potential signiﬁ  -
cance. Furthermore, additional modiﬁ  cation of their 
physicochemical nature is advisable for the purpose 
of generating strong binding to active sites of 
enzyme or peptide molecules.
β-Galactosidosis: Genetic Human 
Disorders Caused by β-Galactosidase 
Gene Mutations
Lysosomal β-galactosidase (EC 3.2.1.23), encoded 
by a gene GLB1 (3p21.33), catalyzes hydrolysis of 
ganglioside GM1 and related glycoconjugates such 
as oligosaccharides derived from glycoproteins and 
keratin sulfate in human somatic cells. Allelic muta-
tions of the gene result in excessive storage of the 
substrates in various cells and tissues.
GM1-gangliosidosis (OMIM 230500) is expressed 
clinically as generalized neurosomatic disease in 
children (infantile form, juvenile form), and rarely 
in adults (adult form), caused by widespread abnormal 
storage of ganglioside GM1, mucopolysaccharide 
keratin sulfate and glycoprotein-derived oligosac-
charides in the central nervous system, skeletal 
system, and other tissues and visceral organs. Speciﬁ  c 
gene mutations are known for each clinical form.
45 
Morquio B disease (OMIM 253010) is another 
clinical phenotype presenting with generalized skel-
etal dysplasia without neurological involvement. 
Again speciﬁ  c gene mutations different from those 
in GM1-gangliosidosis have been identiﬁ  ed.
46 More 
than 100 gene mutations are collected, and success-
ful gene diagnosis is well established using restriction 
enzymes speciﬁ  c to individual mutations.
4
At present only symptomatic therapy is available 
for the brain lesion in human GM1-gangliosidosis 
patients. Enzyme replacement therapy is currently 
in use for clinical practice for Gaucher disease, 
Fabry disease and other lysosomal diseases. 
However, the beneﬁ  cial effect has not been con-
firmed for the brain damage, although general 
somatic signs and symptoms are clearly improved 
by continuous enzyme replacement therapy.
47 
Secretion of feline β-galactosidase was reported in 
the transfected cell culture system, but the effect on 
the central nervous system was not shown.
48
After several years of basic investigations mainly 
for mutant α-galactosidase A in Fabry disease, we 
proposed chemical chaperone therapy for brain 
pathology in GM1-gangliosidosis, using an in vitro 
enzyme inhibitor N-octyl-4-epi-β-valienamine 
(NOEV) (1; Fig. 1A), a chemical compound newly 
produced by organic synthesis described above,
38 as 
a potent stabilizer of mutant β-galactosidase in 
somatic cells from patients with this disorder.
1412
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(A) (B)
Figure 2. Synthetic pathways of valienamines and related compounds.
2A) Synthesis of valienamines and N-alkyl derivatives. (i) H2O2, HCOOH; LAH/THF; Ac2O/Pyrd; (ii) HBr/AcOH; (iii) DBU/toluene; (iv) Br2/CCl4; 
(v) AcONa/MeO(CH2)2OH; NaN3/DMF; (vi) MeONa; Ph3P/MeOH; (vii) MeONa; (MeO)2 CMe2, TsOH/DMF; Ph3P/MeOH; (viii) CH3 (CH2)n–1COCl/
Pyrd; (ix) LAH/THF; (x) aq. AcOH; acidic resin, aq. NH3. 2B) Synthesis of N-alkyl-4-epi-β-valienamines. (i) Br2, Na2CO3/H2O; LAH/THF; 
Ac2O/Pyrd; (ii) HBr/AcOH; (iii) MeONa; aq. H2SO4; Ac2O/Pyrd; (iv) DBU/toluene; (v) MeONa/MeOH; (MeO)2 CMe2, TsOH/DMF; Ac2O/Pyrd; 
(vi) Br2/CCl4; (vii) AcONa/MeO(CH2)2OH; (viii) CH3(CH2)nNH2/DMF; (ix) MeONa/MeOH; aq. AcOH; acidic resin, aq. NH3. 2C) Facile 
transformation of vibo-quercitol into carbahexopyranoses.  
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Genetic Metabolic Diseases: 
Molecular Pathology and an Approach 
to Possible Molecular Therapy
Molecular pathology of inherited metabolic 
diseases can be classiﬁ  ed into the following three 
major conditions.
49
(a)   Biosynthetic defect of the protein in question. 
Mutant enzyme is not synthesized, and accord-
ingly rescue of the protein is not possible.
(b)  Defect of biological activity. In spite of normal 
biosynthesis, the protein does not maintain 
biological activity because of its structural 
abnormality. There is no possibility to restore 
the biological activity of this molecule.
(c)   Unstable mutant protein with normal or 
near-normal biological activity under appropriate 
environmental conditions. The mutant protein 
has normal biological function in its mature 
form. However, it is unstable and rapidly 
degraded immediately after biosynthesis. The 
protein function is expected to be restored if the 
molecule is somehow stabilized and transported 
to the cellular compartment where it is expected 
to exhibit biological activity; the lysosome in 
the case of lysosomal enzyme.13
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We tested these possibilities ﬁ  rst in Fabry disease, 
and found some mutant enzyme proteins were 
unstable at neutral pH in the endoplasmic reticulum/
Golgi apparatus, and rapidly degraded because of 
inappropriate molecular folding.
50 Addition of 
galactose in the culture medium of lymphoblasts 
from Fabry patients and COS-1 cells expressing 
mutant enzyme proteins surprisingly induced a high 
expression of α-galactosidase A activity.
12 However, 
a high concentration of galactose was necessary for 
treatment of these enzyme-deﬁ  cient cells in culture. 
We concluded that a long-term treatment with 
galactose at this high dose was not realistic, although 
a short-term human experiment was reported on the 
beneficial cardiac function in a case of Fabry 
disease.
51 Accordingly we searched for other com-
pounds that could enhance the enzyme activity in 
mutant cells. As stated above, DGJ was found to be 
effective for stabilization and high expression of the 
enzyme activity.
13,52 DGJ showed the chaperone 
effect mainly on mutant α-galactosidae A. Its 
activity toward mutant β-galactosidase was 50-fold 
lower in a culture system experiment.
53
After subsequent extensive molecular analysis 
we reached the following conclusion.
49 A substrate 
analogue inhibitor binds to the misfolded mutant 
lysosomal protein as a kind of molecular chaperone 
(chemical chaperone), to achieve normal molecu-
lar folding at the endoplasmic reticulum/Golgi 
compartment in somatic cells, resulting in forma-
tion of a stable molecular complex at neutral pH. 
The protein-chaperone complex is safely trans-
ported to the lysosome, where it dissociates under 
the acidic conditions, the mutant enzyme remains 
stabilized in its normal folding, and its catalytic 
function is expressed (see below; Fig. 4).
Therapeutic Approach to Brain 
Pathology by Chemical Chaperones
New chaperones: valienamine 
derivatives
We had particular interest in primary neuronopathic 
lysosomal diseases. Accordingly after studies on 
galactose and DGJ for α-galactosidase A, we started 
an extensive search for speciﬁ  c compounds for 
β-galactosidase. No commercially available com-
pound was found as bioactive chaperone. Fortunately 
we came across two synthetic valienamine 
derivatives: β-galactosidase inhibitor N-octyl-4-
epi-β-valienamine (NOEV) and β-glucosidase 
inhibitor N-octyl-β-valienamine (NOV) (1 and 2; 
Fig. 1A). NOV was the ﬁ  rst compound synthesized 
as a glucocerebrosidase inhibitor,
36 and subse-
quently NOEV was synthesized by epimerization 
of NOV.
37 They are speciﬁ  c competitive inhibitors 
of β-galactosidase and β-glucosidase, respectively, 
In our laboratory NOEV studies moved faster than 
NOV simply because of accumulation of more 
experimental data and clinical materials for 
β-galactosidase and GM1-gangliosidosis.
NOEV is a potent inhibitor of lysosomal 
β-galactosidase in vitro. It is stable and soluble in 
methanol or DMSO. The hydrochloride salt 
is freely soluble in water. Molecular weight 
is 287.40. IC50 is 0.125 μM toward human 
β-galactosidase.
14
NOEV is 50-fold more active than DGJ in 
chaperone effect on mutant human β-galactosidase 
in GM1-gangliosidosis. Our calculations suggest 
that at least 10% of normal enzyme activity is 
necessary for washout of the storage substrate in 
lysosomal diseases (Fig. 3). The age of onset in 
4%
Residual enzyme activity
8%
30 y
(10%)
Onset beyond life Onset
20 y
10 y
Figure 3. Correlation between residual β-galactosidase activity 
and clinical onset. The amount of residual enzyme activity shows 
positive parabolic correlation with the age of onset in various 
phenotypic forms of β-galactosidase deficiency disorders. The 
enzyme activity is generally less than 3% of the control mean in 
infantile GM1-gangliosidosis, 3%–6% in juvenile GM1-gangliosidosis, 
and more than 6% in late onset (adult/chronic) GM1-gangliosidosis 
and Morquio B disease. At least 10% of normal enzyme activity is 
necessary for washout of the storage substrate. The age of onset in 
patients expressing enzyme activity above this level is theoretically 
beyond the human life span. This ﬁ  gure is based on the enzyme 
assay results using cultured skin fibroblasts and a synthetic 
ﬂ  uorogenic substrate 4-methylumbelliferyl β-galactopyranoside. In 
this calculation, for technical reasons, substrate speciﬁ  city is not 
taken into account, although mutant enzymes show different spectrum 
in GM1-gangliosidosis and Morquio B disease. 14
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patients expressing enzyme activity above this 
level is theoretically beyond the human life span. 
The same calculation was reported on some other 
lysosomal diseases.
54 We anticipate that the effec-
tive NOEV concentrations in human cells and 
animal tissues are much lower than the IC50 calcu-
lated in vitro, based on the results of tissue 
concentration after oral NOEV administration in 
experimental model mice.
55 In fact, NOEV is 
effective at the IC50 concentration in the culture 
medium for enhancement of mutant enzyme 
activity.
16 We hope it will be clinically used as a 
speciﬁ  c enzyme enhancer without exerting inhib-
itory effect in the cells.
Chaperone experiments 
on culture cells
About one-third of the cultured ﬁ  broblast strains 
from GM1-gangliosidosis patients responded to 
NOEV; mainly from juvenile form and some 
infantile form patients. The effect is mutation-
speciﬁ  c.
16 The R457Q mutant responded to NOEV 
maximally at 0.2 μM, and the R201C or R201H 
mutant at 2 μM. The mouse ﬁ  broblasts express-
ing mutant human β-galactosidase showed essen-
tially the same results.
53 Molecular interaction 
between the chaperone and mutant protein depends 
on the structural modiﬁ  cation of the mutant enzyme 
protein (Sakakibara et al. unpublished data). Addi-
tion of ganglioside mixture in the culture medium 
increased intracellular GM1 in the R201C cells 
causing juvenile GM1-gangliosidosis.
14 This storage 
was almost completely prevented by NOEV.
Chaperone experiments 
on genetically engineered 
GM1-gangliosidosis model mice
For animal studies we developed a knockout 
(KO) mouse strain with complete deﬁ  ciency of 
β-galactosidase,
56 and then a transgenic (Tg) strain 
based on KO, expressing human R201C mutation 
(4% of the enzyme activity in the brain from 
wild-type mice).
14 Both showed neurological dete-
rioration with some difference in severity. Life span 
Normal
Normal
Mutant
Mutant
Mis-
folding folding
Chaperone
Chaperone
Enzyme
Substrate
(dissociation)
ER-Golgi
(neutral pH)
Aggregation
Digestion
Intracellular
Extracellular Uptake
(exogenous) Secretion
Recycling
Lysosome
(acidic pH)
Figure 4. Postulated molecular events between mutant enzyme molecules and chaperone compounds. Mutant enzyme protein is 
unstable in the endoplasmic reticulum (ER)-Golgi compartment at neutral pH, and rapidly degraded or aggregated possibly to cause ER 
stress. An appropriate substrate analogue inhibitor binds to misfolded mutant protein as chemical chaperone at the ER-Golgi compartment 
in somatic cells, resulting in normal folding and formation of a stable complex at neutral pH. The protein-chaperone complex is safely 
transported to the lysosome. The complex is dissociated under the acidic condition and in the presence of excessive storage of the substrate. 
The mutant enzyme remains stabilized, and express catalytic function. The released chaperone is either secreted from the cell or recycled 
to interact with another mutant protein molecule. These molecular events have been partially clariﬁ  ed by analytical and morphological 
analyses, and computer-assisted prediction of molecular interactions. 15
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was 7–10 months for KO and 12–18 months for 
Tg. Neuropathology corresponded to the clinical 
severity.
14 Short-term oral NOEV administration 
resulted in signiﬁ  cant enhancement of the enzyme 
activity in all the R201C mouse tissues examined, 
including the brain.
14 Immunohistochemstry 
revealed an increase in β-galactosidase activity and 
decrease in GM1 and GA1 storage.
Oral NOEV treatment for the R201C Tg mouse 
showed an increase of the NOEV content in the brain 
in parallel with β-galactosidase activity, and GM1 
storage decreased.
55 NOEV disappeared rapidly, 
within a few days after withdrawal. In this study we 
tried a new scoring system for neurological assess-
ment
57 (Table 2). Treatment at the very early clinical 
stage (2 months) resulted in a positive clinical effect 
Table 2. Neurological examination of genetically engineered GM1-gangliosidosis model mice. Each test is 
performed with semi-quantitative time, space, and movement parameters. See Ichinomiya et al.
57 for details.
1. Gait: (hip, knee, spine, and shivering)
Score 0: Normal.
Score 1: Slight gait disturbance.
Score 2: Marked gait disturbance.
Score 3: Marked staggering and shaking; gait impossible.
2. Posture: forelimb (paralysis, deformity)
Score 0: Normal.
Score 1: Starting gait difﬁ  cult and clumsy.
Score 2: Dragging limbs; inversion of dorsum pedis.
Score 3: Complete paralysis; no spontaneous movement.
3. Posture: hind limb (abduction, extention, posture)
Score 0: Normal; smooth joint ﬂ  exion and extension.
Score 1: Slight hip abduction, external rotation, and knee extension; wide-based.
Score 2: Severe hip abduction, external rotation, and knee extension; wide-based. 
Score 3: No spontaneous movement.
4. Trunk (deformity)
Score 0: Normal.
Score 1: Slight back hump.
Score 2: Moderate back hump.
Score 3: Severe back hump.
5. Tail (posture, stiffness)
Score 0: Normal
Score 1: Slight stiffness and elevation.
Score 2: Severe stiffness and elevation.
Score 3: Severe stiffness and elevation with persistent deformity.
6. Avoiding response (pinching tail root with forceps for one second)
Score 0: Strong rejection, avoidance, and squeaking.
Score 1: Slight decrease of response.
Score 2: Trunk torsion; hind limb extension.
Score 3: No response.
7. Rolling over (turning the tail root three times to left and right)
Score 0: Extending four limbs, resisting passive rolling.
Score 1: Slow passive rolling; prompt recovery.
(Continued)16
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Table 2. (Continued)
Score 2: Markedly slow passive rolling; delayed recovery.
Score 3: Posture change impossible; slow body movement.
8. Body righting acting on head (response to vertical hanging, head down by holding tail tip, and quick 
upward movements)
Score 0: Strong upward righting reaction of the head.
Score 1: Slight decrease in response.
Score 2: Marked decrease in response.
Score 3: No response; trunk rotation only.
9. Parachute reﬂ  ex (response to vertical hanging, head down by holding tail tip, and quick downward 
movement, three times, within 30 sec)
Score 0: Extension and abduction of hind limbs; continuous knee extension.
Score 1: Slight decrease in response; intermittent knee extension.
Score 2: Marked decrease in response; ﬂ  exion and adduction of hind limbs; slow movements.
Score 3: No response; continuous ﬂ  exion and adduction of hind limbs.
10. Horizontal wire netting (stepping through interstice during walking on horizontal wire netting)
Score 0: No stepping into interstice.
Score 1: 21–30 sec before stepping into interstice.
Score 2: 11–20 sec before stepping into interstice.
Score 3: 0–10 sec before stepping into interstice.
11. Vertical wire netting (clinging and holding body on vertical wire netting)
Score 0: Stay for 30 sec.
Score 1: Stay for 21–30 sec before falling.
Score 2: Stay for 11–20 sec before falling.
Score 3: Stay for 0–10 sec before falling.
Table 3. Effect of NOEV on GM1-gangliosidosis Tg mice. Experimental mice were orally fed with water 
(0 mM NOEV) or NOEV solution (1 mM) for 6 months. Total assessment scores were calculated for each group. 
Value = mean ± SEM (n); ns = statistically not signiﬁ  cant. For details see Suzuki et al.
55
NOEV 0 mM 1 mM t test
2 months 1.72 ± 0.19 (32) 1.53 ± 0.17 (17) ns
3 months 2.18 ± 0.38 (11) 1.77 ± 0.24 (17) ns
4 months 2.53 ± 0.29 (19) 2.06 ± 0.23 (16) ns
5 months 3.35 ± 0.33 (17) 2.40 ± 0.32 (15) p < 0.05
6 months 3.90 ± 0.31 (30) 2.81 ± 0.25 (16) p < 0.05
7 months 4.88 ± 0.57 (17) 3.43 ± 0.20 (14) p < 0.05
within a few months, although complete arrest or 
prevention of disease progression was not achieved 
under this experimental condition (Table 3). The 
latency before the clinical effect was longer if the 
therapy was started in the late symptomatic stage 
(6 months). We concluded that NOEV treatment at 
the early stage of disease is mandatory for prevention 
of the brain damage.
This result indicated the following sequence of 
events in the mouse brain.
49 After oral administra-
tion, NOEV goes directly into the bloodstream 
without intestinal digestion, is delivered to the 17
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brain through the blood-brain barrier, and restore 
the mutant β-galactosidase activity, resulting in 
substrate digestion and clinical improvement. No 
speciﬁ  c adverse effects have been observed for at 
least 6 months of continuous oral administration. 
For achievement of clinical drug development, 
however, we need to study further possible 
adverse effects and to establish the optinal dose 
and frequency of administration in order to achieve 
the best clinical effect.
Molecular Mechanisms 
of Chaperone Effect in Lysosomal 
Disease
As described above, β-galactosidase gene mutations 
result in excessive accumulation of substrates and 
various clinical phenotypes: GM1-gangliosidosis 
and Morquio B disease. Single base substitutions 
do not necessarily lead to a complete loss of enzyme 
function. However, the enzyme activity is not 
always expressed even if the potential catalytic 
function is not completely lost, simply because of 
intracellular instability of the mutant enzyme mol-
ecule due to inappropriate or incorrect protein fold-
ing. Molecular pathology of this type occurs at least 
in one-third of the patients with β-galactosidase 
deficiency.
16 Chemical chaperone corrects the 
molecular abnormality of this type, and assists 
intracellular transport to the lysosome, ﬁ  nally 
releasing the mutant enzyme as a stable bioactive 
protein (Fig. 4).
We postulated that enzyme-chaperone binding 
would become less strong under the acidic 
condition in the lysosome. Then the mutant enzyme 
molecule is released and stable catalytic activity 
appears. However, the precise mechanism of this 
NOEV effect is unknown at present. We therefore 
started computational analysis for prediction of 
molecular interactions between the β-galactosidase 
protein and the chaperone compound NOEV.
First, the three-dimensional structure of human 
enzyme was predicted employing a homology 
modeling method 3D-JURY,
58,59 because the 
structure of this enzyme is not yet available. 
Penicillium sp. β-galactosidase was used as the 
template structure for homology modeling, and the 
predicted structure of human β-galactosidase has 
been obtained as shown in Figure 5A.
Second, plausible conformation of β-galactosidase-
NOEV complex was determined in support of 
AUTODOCK4.
60 The conformation was subjected to 
TIM barrel
Active site
A
B
Figure 5. Computationally predicted structure of β-galactosidase 
and its conformation of β-galactosidase and NOEV complex. 
5A) Sequence identity in the front part was enough to reconstruct its 
structure and formed a typical TIM barrel domain that is generally 
found in glycoside hydrolases. In alignment of this part, active resi-
dues of both human and Penicillium sp. β-galactosidase molecules 
were well matched. 5B) Docking of β-galactosidase and NOEV was 
performed. In the complex of β-galactosidase and NOEV in pH7, the 
ring part of NOEV was settled in the active pocket. Oxygen of a 
glutamic acid in β-galactosidase and hydroxyl of amido in NOEV 
interacted via hydrogen bonding.
further structural optimization. The result of the 
complex structure was successfully computed by 
AUTODOCK4 (Fig. 5B).
Third, the binding free energy of the two mol-
ecules in the complex was calculated by using 18
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AMBER9.
61 The computed binding free energy 
was −20.08 (kcal/mol) at pH 7.
Fourth, we calculated the effect of low pH in 
the lysosome on the binding afﬁ  nity between the 
β-galactosidase and NOEV molecules. The low pH 
effect was represented as protonation of charged 
residues estimated by PROPKA.
62 The computed 
binding free energy at pH 5 was −18.06 (kcal/mol); 
higher than that at pH 7. This result indicates that 
afﬁ  nity between β-galactosidase and NOEV is 
weakened at pH 5 compared with that at pH 7. 
Consequently, we concluded that (1) the enzyme-
NOEV complex has lower free energy than the 
unbound enzyme, and (2) protonation of an active 
site residue causes free energy change consistent 
with the chemical chaperone hypothesis.
Conclusion
This new therapeutic strategy (chaperone therapy) 
is in principle applicable to all lysosomal diseases, 
if a speciﬁ  c compound is developed for each 
enzyme in question. We have already conﬁ  rmed 
the effect in Fabry disease, GM1-gangliosidosis, 
and Gaucher disease. Other related diseases also 
are currently studied by other investigators.
63,64 
Theoretically this principle can be applied to all 
other lysosomal diseases. Furthermore, there may 
well be other genetic diseases to be considered, 
if molecular pathology in somatic cells has been 
clariﬁ  ed in detail. We hope studies in this direc-
tion will disclose a new aspect of molecular 
therapy for inherited metabolic diseases with 
central nervous system involvement in the near 
future.
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